Banz Yara, Rieben Robert, Zobrist Claudia, Meier Pascal, Shaw Sidney, Lanz Jonas, Carrel Thierry, Berdat Pascal
Department of Clinical Research, University of Bern, Bern, Switzerland; Department of Cardiovascular Surgery, University Hospital, Bern, Switzerland.
Eur J Cardiothorac Surg. 2008 Sep;34(3):653-60. doi: 10.1016/j.ejcts.2008.05.024. Epub 2008 Jun 24.
Contact of blood with artificial surfaces and air as well as ischemia/reperfusion injury to the heart and lungs mediate systemic and local inflammation during cardiopulmonary bypass (CPB). Activation of complement and coagulation cascades leads to and accompanies endothelial cell damage. Therefore, endothelial-targeted cytoprotection with the complement inhibitor and endothelial protectant dextran sulfate (DXS, MW 5000) may attenuate CBP-associated myocardial and pulmonary injury.
Eighteen pigs (DXS, n=10; phosphate buffered saline [PBS], n=8) underwent standard cardiopulmonary bypass. After aortic cross-clamping, cardiac arrest was initiated with modified Buckberg blood cardioplegia (BCP), repeated after 30 and 60 min with BCP containing either DXS (300 mg/10 ml, equivalent to 5mg/kg) or 10 ml of PBS. Following 30 min reperfusion, pigs were weaned from CPB. During 2h of observation, cardiac function was monitored by echocardiography and invasive pressure measurements. Inflammatory and coagulation markers were assessed regularly. Animals were then sacrificed and heart and lungs analyzed.
DXS significantly reduced CK-MB levels (43.4+/-14.8 ng/ml PBS, 35.9+/-11.1 ng/ml DXS, p=0.042) and significantly diminished cytokine release: TNFalpha (1507.6+/-269.2 pg/ml PBS, 222.1+/-125.6 pg/ml DXS, p=0.0071), IL1beta (1081.8+/-203.0 pg/ml PBS, 110.7+/-79.4 pg/ml DXS, p=0.0071), IL-6 (173.0+/-91.5 pg/ml PBS, 40.8+/-19.4 pg/ml DXS, p=0.002) and IL-8 (304.6+/-81.3 pg/ml PBS, 25.4+/-14.2 pg/ml DXS, p=0.0071). Tissue endothelin-1 levels were significantly reduced (6.29+/-1.90 pg/100mg PBS, 3.55+/-1.15 pg/100mg DXS p=0.030) as well as thrombin-anti-thrombin formation (20.7+/-1.0 microg/ml PBS, 12.8+/-4.1 microg/ml DXS, p=0.043). Also DXS reduced cardiac and pulmonary complement deposition, neutrophil infiltration, hemorrhage and pulmonary edema (measured as lung water content, 81+/-3% vs 78+/-3%, p=0.047), indicative of attenuated myocardial and pulmonary CPB-injury. Diastolic left ventricular function (measured as dp/dt(min)), pulmonary artery pressure (21+/-3 mmHg PBS, 19+/-3 mmHg DXS, p=0.002) and right ventricular pressure (21+/-1 mmHg PBS, 19+/-3 mmHg DXS p=0.021) were significantly improved with the use of DXS.
Addition of DXS to the BCP solution ameliorates post-CPB injury and to a certain extent improves cardiopulmonary function. Endothelial protection in addition to myocyte protection may improve post-CPB outcome and recovery.
血液与人工表面及空气的接触,以及心脏和肺部的缺血/再灌注损伤,在体外循环(CPB)期间介导全身和局部炎症反应。补体和凝血级联反应的激活会导致并伴随内皮细胞损伤。因此,使用补体抑制剂和内皮保护剂硫酸葡聚糖(DXS,分子量5000)进行内皮靶向细胞保护,可能减轻CPB相关的心肌和肺损伤。
18头猪(DXS组,n = 10;磷酸盐缓冲盐水[PBS]组,n = 8)接受标准体外循环。主动脉交叉夹闭后,用改良的巴克伯格血液停搏液(BCP)诱导心脏停搏,30分钟和60分钟后分别用含DXS(300mg/10ml,相当于5mg/kg)或10ml PBS的BCP重复诱导。再灌注30分钟后,使猪脱离CPB。在2小时的观察期内,通过超声心动图和有创压力测量监测心脏功能。定期评估炎症和凝血标志物。然后处死动物,对心脏和肺进行分析。
DXS显著降低CK-MB水平(PBS组为43.4±14.8ng/ml,DXS组为35.9±11.1ng/ml,p = 0.042),并显著减少细胞因子释放:肿瘤坏死因子α(TNFα)(PBS组为1507.6±269.2pg/ml,DXS组为222.1±125.6pg/ml,p = 0.0071)、白细胞介素1β(IL1β)(PBS组为1081.8±203.0pg/ml,DXS组为110.7±79.4pg/ml,p = 0.0071)、白细胞介素-6(IL-6)(PBS组为173.0±91.5pg/ml,DXS组为40.8±19.4pg/ml,p = 得0.002)和白细胞介素-8(IL-8)(PBS组为304.6±81.3pg/ml,DXS组为25.4±14.2pg/ml,p = 0.0071)。组织内皮素-1水平显著降低(PBS组为6.29±1.90pg/100mg,DXS组为3.55±1.15pg/100mg,p = 0.030),凝血酶-抗凝血酶复合物形成也显著降低(PBS组为20.7±1.0μg/ml,DXS组为12.8±4.1μg/ml,p = 0.043)。DXS还减少了心脏和肺部的补体沉积、中性粒细胞浸润、出血和肺水肿(以肺含水量衡量,分别为81±3%和78±3%,p = 0.047),表明心肌和肺CPB损伤减轻。使用DXS后,舒张期左心室功能(以dp/dt(min)衡量)、肺动脉压(PBS组为21±3mmHg,DXS组为19±3mmHg,p = 0.002)和右心室压(PBS组为21±1mmHg,DXS组为19±3mmHg,p = 0.021)均得到显著改善。
在BCP溶液中添加DXS可减轻CPB后损伤,并在一定程度上改善心肺功能。除心肌保护外,内皮保护可能改善CPB后的预后和恢复情况。